Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory, Cross-sectional Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (greater than 3 Years) With Lopinavir / Ritonavir Monotherapy.

Next Previous
Search
Trial Profile

Exploratory, Cross-sectional Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (greater than 3 Years) With Lopinavir / Ritonavir Monotherapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Feb 2012 Status changed from recruiting to completed.
    • 18 Nov 2010 Actual initiation date changed from Sept 2009 to Aug 2009 as reported by ClinicalTrials.gov.
    • 18 Nov 2010 Planned End Date changed from 1 Sep 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top